Capricor Therapeutics (NASDAQ:CAPR) Lowered to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Capricor Therapeutics (NASDAQ:CAPR) from a sell rating to a strong sell rating in a report released on Saturday morning.

A number of other research firms have also weighed in on CAPR. LADENBURG THALM/SH SH lowered Capricor Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday. Maxim Group downgraded Capricor Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday. Piper Sandler cut Capricor Therapeutics from an “overweight” rating to a “neutral” rating and set a $2.00 price target on the stock. in a report on Thursday. HC Wainwright restated a “neutral” rating on shares of Capricor Therapeutics in a research note on Monday, July 27th. Finally, Alliance Global Partners lowered shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 price objective for the company. in a report on Tuesday, July 28th. Ten investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Reduce” and an average price target of $29.15.

Capricor Therapeutics Stock Performance

Shares of Capricor Therapeutics stock opened at $3.85 on Friday. The company has a market capitalization of $222.95 million, a P/E ratio of -1.66 and a beta of 0.42. The company has a fifty day moving average of $23.00 and a 200 day moving average of $26.77. Capricor Therapeutics has a fifty-two week low of $2.96 and a fifty-two week high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). Analysts forecast that Capricor Therapeutics will post -1.62 EPS for the current year.

Insider Activity at Capricor Therapeutics

In other news, CFO Anthony Bergmann sold 24,100 shares of the firm’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $30.38, for a total transaction of $732,158.00. Following the completion of the transaction, the chief financial officer owned 11,223 shares in the company, valued at $340,954.74. This trade represents a 68.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last ninety days, insiders have sold 25,000 shares of company stock worth $759,158. 9.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Capricor Therapeutics

A number of hedge funds have recently made changes to their positions in CAPR. KBC Group NV purchased a new position in Capricor Therapeutics during the 1st quarter valued at approximately $44,000. ACT Capital Management LLC purchased a new stake in shares of Capricor Therapeutics during the 4th quarter worth approximately $43,000. Allworth Financial LP raised its holdings in shares of Capricor Therapeutics by 5,021.5% during the 4th quarter. Allworth Financial LP now owns 3,329 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 3,264 shares in the last quarter. State of Wyoming boosted its position in shares of Capricor Therapeutics by 76.0% during the 4th quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock valued at $128,000 after acquiring an additional 1,913 shares during the last quarter. Finally, Royal Bank of Canada boosted its position in shares of Capricor Therapeutics by 12.4% during the 4th quarter. Royal Bank of Canada now owns 5,040 shares of the biotechnology company’s stock valued at $146,000 after acquiring an additional 557 shares during the last quarter. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Capricor Therapeutics

Here are the key news stories impacting Capricor Therapeutics this week:

• Neutral Sentiment: The FDA’s Cellular, Tissue and Gene Therapies Advisory Committee voted 9-3 that available evidence did not support Deramiocel’s effectiveness. The vote is non-binding, so the FDA could still reach a different decision, but it is a significant setback for Capricor’s regulatory path. Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel
• Neutral Sentiment: FDA briefing materials and media reports questioned whether Deramiocel met its pre-specified cardiac endpoint and challenged Capricor’s interpretation of Phase 3 results. The dispute centers on changes to the statistical analysis plan that allegedly were not agreed to by the FDA before the company resubmitted its biologics license application. Capricor plummets after FDA panel votes against Duchenne heart disease therapy
• Negative Sentiment: Multiple law firms have announced securities-fraud investigations or filed shareholder class actions alleging that Capricor made materially misleading statements or failed to disclose regulatory and clinical-data risks related to Deramiocel. The lawsuits add legal, financial and reputational risk, although the allegations have not been proven. Investors have been encouraged to contact the firms, with some notices citing a September 28, 2026 deadline. CAPR Investor Alert: Class Action Lawsuit Filed on Behalf of Capricor Therapeutics Investors
• Negative Sentiment: Analysts responded by cutting ratings, including downgrades from Cantor Fitzgerald, Maxim Group, Ladenburg Thalmann and Alliance Global Partners. Cantor moved to Neutral with a $3.50 price target, while JonesTrading reaffirmed a Hold rating. Capricor Therapeutics downgraded by Cantor Fitzgerald

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.